Adma Biologics Inc. (ADMA)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Can Asceniv Help ADMA Stock Combat IG Market Challenges?
Asceniv drives ADMA's growth with rising adoption and real-world evidence, while competitive pressure weighs on Bivigam sales.
ADMA Biologics: The Earnings Reset Still Leaves More Upside
ADMA Biologics faces a lower earnings base after some challenging times, but ASCENIV remains its key growth driver. Despite reduced long-term targets, Q2 saw ASCENIV revenue up 24%, gross margin at 69%, and improved receivable collection, supporting valuation confidence. My Buy thesis rests on continued ASCENIV growth from the reset base, not a reversal of prior shocks or restored guidance.
ADMA Q2 Earnings Meet, Revenues Miss on Bivigam Weakness
ADMA Biologics matches earnings estimates, misses on revenues and maintains its 2026 outlook as strong Asceniv growth offsets continued pressure on Bivigam.
ADMA Biologics, Inc. (ADMA) Q2 2026 Earnings Call Transcript
ADMA Biologics, Inc. (ADMA) Q2 2026 Earnings Call Transcript
ADMA Biologics Q2 Earnings Call Highlights
ADMA Biologics NASDAQ: ADMA reported second-quarter revenue growth of 2% as increased sales of its ASCENIV immune globulin product offset pressure on BIVIGAM in the standard immunoglobulin market. The company reiterated its full-year financial outlook and said it remains on track to meet or exceed those expectations.
Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note
Adma Biologics (ADMA) closed the most recent trading day at $8.46, moving 2.42% from the previous trading session.
Wall Street Analysts See Adma Biologics (ADMA) as a Buy: Should You Invest?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Adma Biologics (ADMA) Rises Higher Than Market: Key Facts
In the latest trading session, Adma Biologics (ADMA) closed at $8.48, marking a +2.54% move from the previous day.
Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note
The latest trading day saw Adma Biologics (ADMA) settling at $8.59, representing a -1.83% change from its previous close.
Adma Biologics (ADMA) Suffers a Larger Drop Than the General Market: Key Insights
Adma Biologics (ADMA) closed the most recent trading day at $8.97, moving 1.21% from the previous trading session.
Is It Worth Investing in Adma Biologics (ADMA) Based on Wall Street's Bullish Views?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Is ADMA Stock's 13.5% Monthly Gain a Sign of Recovery?
ADMA shares rebound 13.5% in a month after a steep decline, even as lowered 2026 guidance and IG market competition continue to weigh on sentiment.
